Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved?

Full text
Author(s):
da Silva, Lais Teodoro [1] ; Santillo, Bruna Tereso [1] ; de Almeida, Alexandre [1] ; da Silva Duarte, Alberto Jose [1] ; Oshiro, Telma Miyuki [1]
Total Authors: 5
Affiliation:
[1] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Lab Invest Dermatol & Imunodeficiencias, Sao Paulo - Brazil
Total Affiliations: 1
Document type: Review article
Source: FRONTIERS IN IMMUNOLOGY; v. 9, DEC 18 2018.
Web of Science Citations: 5
Abstract

Harnessing dendritic cells (DC) to treat HIV infection is considered a key strategy to improve anti-HIV treatment and promote the discovery of functional or sterilizing cures. Although this strategy represents a promising approach, the results of currently published trials suggest that opportunities to optimize its performance still exist. In addition to the genetic and clinical characteristics of patients, the efficacy of DC-based immunotherapy depends on the quality of the vaccine product, which is composed of precursor-derived DC and an antigen for pulsing. Here, we focus on some factors that can interfere with vaccine production and should thus be considered to improve DC-based immunotherapy for HIV infection. (AU)

FAPESP's process: 18/12460-0 - Production and characterization of polarized dendritic cells aDC1 for use in anti-HIV immunotherapy
Grantee:Laís Teodoro da Silva
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 16/25212-9 - Therapeutic vaccine based on aDC1 dendritic cells pulsed with inactivated autologous virus for the control of viremia after ATI in HIV infected individuals
Grantee:Alberto José da Silva Duarte
Support Opportunities: Research Projects - Thematic Grants